Prognosis of Patients With Heart Failure Receiving Autologous Myoblast Patches ― Comparison of Single-Arm Trial Data to Registry Data ―
Shigeru Miyagawa(The University of Osaka), Yoshiki Sawa(Osaka Police Hospital), Yasushi Sakata(Osaka University), Chikako Matsuo(The University of Osaka), Yukako Nitta(The University of Osaka), Masahiro Takeuchi(The University of Tokyo), Yukiko Imanishi(The University of Osaka), Tomomi Shimamoto(The University of Osaka), Satoshi Kainuma(National Cerebral and Cardiovascular Center)
Cited by 5
Related Papers
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
|Nature Medicine|2022|889
Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
|Journal of Clinical Oncology|2014|777
Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases
|Nature Genetics|2020|599
In vivo transfection of cis element “decoy” against nuclear factor- κB binding site prevents myocardial infarction
|Nature Medicine|1997|589
Hepatocyte growth factor gene therapy of liver cirrhosis in rats
|Nature Medicine|1999|588